Reduced SOCS2 protein expression is associated with a poorer outcome in diverse human cancers, such as colorectal cancer [31], breast carcinoma [32], and hepatocellular carcinoma [33], suggesting SOCS2 may have some utility as a prognostic biomarker. This evidence concerns the gene SOCS2 and breast carcinoma.